January #67 : Nukelier Fusion - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Here Comes the Cure

Magical Mystery Cure

Cancer Rising

One To Watch: Frank Oldham

Opposite of Sex

Are the Kids Alright?

Paint by Numbers

Withdrawal Symptoms

Say What?

Safe-Surf Guidelines

The Down-Low Lowdown

You Can't Go Home Again

Teach Your Children Well

Personal Transformations

Lost in Disk Space

Buenas Noches

No Intermission

Tribute: Jacqueline M. Fuentes


Cardio Calculus

Herb Of The Month: Green Tea

When Chemo Calls


Kiss Lipo BUH-BYE?

Tonic for Two

Nukelier Fusion

Peppier Paps

Comfort Zone

On the Brink of Ink

Cyber Rx

Love's Labor

Heartbreak Hotel

Editor's Letter


01.01.93 Defining Moment

The Baby Blues

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

January 2001

Nukelier Fusion

by Lark Lands

The hope: Shed the side effects, complex dosing schedules and pill burden of protease inhibitors (PIs) by switching to kindler, gentler all-nucleoside-analogue regimens. The fear: popping three same-class compounds might not keep the bug at bay. Now two studies offer insight on who may be able to go wall-to-wall nukes. Among HIVers averaging 20 months on HAART, undetectable viral loads and no prior virological failure, Vancouver's Julio Montaner, MD, pitted 106 HAARTers who stayed on two-nuke, one-PI regimens against 105 who pitched the protease for the nuke abacavir (Ziagen) plus their other nucleosides. At 48 weeks, treatment failure -- virological failure or a therapy stop -- occurred in 26 PI-takers but only 13 who abaca-veered. That three times as many PI-poppers stopped their regimens because of side effects accounts for much of the difference. Viral rebound (two consecutive viral loads above 400) was low in both groups, appearing in only four all-nukers and two still on PIs. Abacavir-takers also reported more med-taking ease and treatment satisfaction and showed lower cholesterol and triglycerides trends.

So going nukelier might look tempting if you've never had drug failure. But the Swiss cohort's Simplified Maintenance Therapy (SMT) study yields important cautions. SMT was similar to Montaner's study -- HIVers could stay on PI-powered regimens or switch to abacavir and Combivir (AZT plus 3TC). But there was one key difference: 48 percent of those on PIs and 36 percent of switchers had a pre-HAART liaison with AZT. At a median 68 weeks, therapy failure for any reason (including virologic failure, treatment change, discontinuation or death) occurred in 29 percent of PI-poppers and 25 percent of abacavir-takers. But the virologic failure occurred in 15 percent of those on abacavir/Combivir and only 6 percent of PI-takers. Turns out that prior suboptimal AZT use quadrupled the odds of virologic failure. So if AZT was always used in successful HAART, switching to all nukes may be feasible. But with a mono- or dual-AZT past, sticking with a protease-spritzed cocktail may up the odds for keeping the virus down.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.